Cargando…

International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial

BACKGROUND: Regional differences in risk of diabetes mellitus and cardiovascular outcomes in people with impaired glucose tolerance are poorly characterized. Our objective was to evaluate regional variation in risk of new‐onset diabetes mellitus, cardiovascular outcomes, and treatment effects in par...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harumi Higuchi dos Santos, Marilia, Sharma, Abhinav, Sun, Jie‐Lena, Pieper, Karen, McMurray, John J.V., Holman, Rury R., Lopes, Renato D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5523624/ https://www.ncbi.nlm.nih.gov/pubmed/28087508 http://dx.doi.org/10.1161/JAHA.116.003892

Ejemplares similares

Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial
por: Preiss, David, et al.
Publicado: (2012)

Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study
por: Shen, Lan, et al.
Publicado: (2013)

Relationship between baseline physical activity assessed by pedometer count and new-onset diabetes in the NAVIGATOR trial
por: Kraus, William E, et al.
Publicado: (2018)

Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease
por: Bethel, M. Angelyn, et al.
Publicado: (2023)

Health utilities in Chinese patients with coronary heart disease and impaired glucose tolerance (ACE): A longitudinal analysis of a randomized, double‐blind, placebo‐controlled trial
por: Leal, José, et al.
Publicado: (2022)

Evaluation of a Self-Administered Oral Glucose Tolerance Test
por: Bethel, M. Angelyn, et al.
Publicado: (2013)

Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study
por: Preiss, David, et al.
Publicado: (2015)

Detection of Subclinical Trastuzumab-Induced Cardiotoxicity in Patients with Breast Cancer
por: dos Santos, Marília Harumi Higuchi
Publicado: (2013)

Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes
por: Coleman, Ruth L., et al.
Publicado: (2019)

Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS
por: Nauck, Michael A., et al.
Publicado: (2019)

Cardiovascular events and atherosclerosis in patients with type 2 diabetes and impaired glucose tolerance: What are the medical treatments to prevent cardiovascular events in such patients?
por: Ishii, Hideki
Publicado: (2022)

SOLOIST‐WHF and updated meta‐analysis: sodium–glucose co‐transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure
por: Docherty, Kieran F., et al.
Publicado: (2020)

The impact of individualised cardiovascular disease (CVD) risk estimates and lifestyle advice on physical activity in individuals at high risk of CVD: a pilot 2 × 2 factorial understanding risk trial
por: Price, Hermione C, et al.
Publicado: (2008)

Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
por: Davis, Timothy M. E., et al.
Publicado: (2022)

Insights into physical activity and cardiovascular disease risk in young children: IDEFICS study
por: McMurray, Robert G
Publicado: (2013)

Development and validation of a model to predict cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease
por: Stevens, Susanna R., et al.
Publicado: (2022)

Navigating the Evolving Landscape of Cardiovascular Training and Education
por: Faza, Nadeen N., et al.
Publicado: (2022)

Effect of α-lipoic acid and exercise training on cardiovascular disease risk in obesity with impaired glucose tolerance
por: McNeilly, Andrea M, et al.
Publicado: (2011)

Metformin modifies the exercise training effects on risk factors for cardiovascular disease in impaired glucose tolerant adults
por: Malin, Steven K., et al.
Publicado: (2013)

Pharmacogenetic analyses of variations of measures of cardiovascular risk in Alzheimer's dementia
por: de Oliveira, Fabricio Ferreira, et al.
Publicado: (2019)

Predicting Outcomes Over Time in Patients With Heart Failure, Left Ventricular Systolic Dysfunction, or Both Following Acute Myocardial Infarction
por: Lopes, Renato D., et al.
Publicado: (2016)

Relation of Adiponectin to Glucose Tolerance Status, Adiposity, and Cardiovascular Risk Factor Load
por: Wolfson, N., et al.
Publicado: (2012)

Sympathetic NPY controls glucose homeostasis, cold tolerance, and cardiovascular functions in mice
por: Kumari, Raniki, et al.
Publicado: (2023)

Pathogenetic Mechanisms and Cardiovascular Risk: Differences between HbA(1c) and oral glucose tolerance test for the diagnosis of glucose tolerance
por: Bianchi, Cristina, et al.
Publicado: (2012)

Proinflammatory and Prothrombotic State in Subjects with Different Glucose Tolerance Status before Cardiovascular Disease
por: Isordia-Salas, Irma, et al.
Publicado: (2014)

Performance of the UK Prospective Diabetes Study Risk Engine and the Framingham Risk Equations in Estimating Cardiovascular Disease in the EPIC- Norfolk Cohort
por: Simmons, Rebecca K., et al.
Publicado: (2009)

Discriminatory performance of adiponectin and leptin in the identification of impaired glucose tolerance: The Guangzhou Biobank Cohort Study - Cardiovascular Disease Subcohort
por: Toulis, Konstantinos A., et al.
Publicado: (2018)

‘Hearts and minds’: association, causation and implication of cognitive impairment in heart failure
por: Cannon, Jane A, et al.
Publicado: (2015)

Variations in the Ghrelin Receptor Gene Associate with Obesity and Glucose Metabolism in Individuals with Impaired Glucose Tolerance
por: Mager, Ursula, et al.
Publicado: (2008)

Glucose metabolism in cardiovascular surgery
por: Lazzeri, C, et al.
Publicado: (2010)

A Guide to Navigating Virtual Cardiovascular Disease Fellowship Interviews
por: Reza, Nosheen, et al.
Publicado: (2020)

Navigating COVID-19 Testing: Special Considerations for the Cardiovascular Clinician
por: Shah, Palak, et al.
Publicado: (2020)

Longer time to peak glucose during the oral glucose tolerance test increases cardiovascular risk score and diabetes prevalence
por: Lin, Yi-Chun, et al.
Publicado: (2017)

Brain-Derived Neurotrophic Factor during Oral Glucose Tolerance Test Predicts Cardiovascular Outcomes
por: Lee, I-Te, et al.
Publicado: (2020)

The Africans in America study demonstrates that subclinical cardiovascular risk differs by etiology of abnormal glucose tolerance
por: Wentzel, Annemarie, et al.
Publicado: (2022)

Benchmarking the Cost-Effectiveness of Interventions Delaying Diabetes: A Simulation Study Based on NAVIGATOR Data
por: Leal, Jose, et al.
Publicado: (2020)

Sex differences in prognostic role of fasting glucose, Oral glucose tolerance, and HbA1c in diabetic cardiovascular disease
por: Yoshida, Yilin, et al.
Publicado: (2023)

Voice-based screening for SARS-CoV-2 exposure in cardiovascular clinics
por: Sharma, Abhinav, et al.
Publicado: (2021)

Glucose Control and Cardiovascular Disease: Is it important? No
por: Conget, Ignacio, et al.
Publicado: (2009)

Effect of Glucose Levels on Cardiovascular Risk
por: Poznyak, Anastasia V., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m1j2d97c394kehhrcu36lh7h3q